NUVL · As filed with the SEC
Nuvalent cash flow statement, by quarter
The statement as Nuvalent presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||
| Net loss | (109,279,000) | — | — | — | (84,582,000) | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Stock-based compensation expense | 28,880,000 | — | — | — | 20,380,000 | — | — |
| Net accretion on marketable securities | — | — | — | — | (4,283,000) | — | — |
| Net accretion on marketable securities | (1,830,000) | — | — | — | — | — | — |
| Change in fair value of related party revenue share liability | 2,570,000 | — | — | — | 1,430,000 | — | — |
| Other non-cash | 120,000 | — | — | — | 32,000 | — | — |
| Changes in operating assets and liabilities: | |||||||
| Prepaid expenses and other current assets | (3,000) | — | — | — | 818,000 | — | — |
| Other assets | (3,036,000) | — | — | — | (9,183,000) | — | — |
| Accounts payable | (7,688,000) | — | — | — | 20,940,000 | — | — |
| Accrued expenses and other liabilities | (2,133,000) | — | — | — | (373,000) | — | — |
| Net cash used in operating activities | (92,399,000) | — | — | — | (54,821,000) | — | — |
| Cash flows from investing activities: | |||||||
| Purchases of marketable securities | (200,963,000) | — | — | — | (277,177,000) | — | — |
| Proceeds from maturities and sales of marketable securities | 181,549,000 | — | — | — | 302,594,000 | — | — |
| Net cash provided by (used in) investing activities | (19,414,000) | — | — | — | 25,417,000 | — | — |
| Cash flows from financing activities: | |||||||
| Proceeds from issuance of common stock, net | 10,135,000 | — | — | — | 4,554,000 | — | — |
| Payments of equity issuance costs | (334,000) | — | — | — | (6,000) | — | — |
| Payments of insurance costs financed by a third-party | — | 0† | 0† | 0† | 0 | 0† | 0† |
| Net cash provided by financing activities | 9,801,000 | — | — | — | 4,548,000 | — | — |
| Net decrease in cash and cash equivalents | (102,012,000) | — | — | — | (24,856,000) | — | — |
| Cash and cash equivalents at beginning of period | 261,745,000 | 115,752,000 | 127,470,000 | 120,835,000 | 145,691,000 | 369,244,000 | 77,700,000 |
| Cash and cash equivalents at end of period | 159,733,000 | 261,745,000 | 115,752,000 | 127,470,000 | 120,835,000 | 145,691,000 | 369,244,000 |
| Supplemental disclosure of noncash investing and financing information: | |||||||
| Operating lease right-of-use asset | 0 | — | — | — | 798,000 | — | — |
| Equity issuance costs | — | 336,000† | — | — | — | (231,000)† | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.